Medication info

Rinac Duo Tablet 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanpung Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
60 tablets/box [10 tablets/PTPX6]
Approval status
Expired

MFDS item code 202009051 · Approved 2020.12.21

This product's status changed to Expired on 2025.12.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no prior experience of pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Hanpung Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulties in blood sugar control
View approved original text

This medication is used alongside diet and exercise to assist in blood sugar control for adults with type 2 diabetes. It can be administered when prior treatment with diabetes medications has not been given or when blood sugar control is difficult with monotherapy. It may also be used as a substitute or in conjunction with monotherapy using metformin or a combined therapy of linagliptin and metformin when insufficient. It effectively helps to control blood sugar levels when used in combination with sulfonylureas, insulin, or empagliflozin. This medication is utilized to improve blood sugar control in various medication treatment scenarios.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no prior experience of pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication contains metformin and linagliptin, which may pose a risk of serious side effects such as lactic acidosis. Lactic acidosis is rare but can be very dangerous, particularly in patients with decreased kidney function or those with heart or liver issues, and should be avoided in these cases. This medication should not be used in patients with allergies to its ingredients or in patients with type 1 diabetes, diabetic ketoacidosis, or diabetic pre-coma. It is contraindicated in patients with severe impairment of kidney function or acute infections, dehydration, severe trauma, shock, acute myocardial infarction, etc., which may affect kidney function. It is advisable to avoid this medication in pregnant or potentially pregnant women, as well as during breastfeeding. This medication may cause hypoglycemia; therefore, caution is needed when used together with insulin or sulfonylureas, and dose adjustments may be required. To reduce the risk of lactic acidosis, kidney function should be regularly monitored, and the medication should be ceased immediately in cases of dehydration, severe vomiting, or diarrhea. If iodine-based contrast media is administered during radiological examinations, the use of this medication should be temporarily suspended before and after the examination due to the risk of kidney failure. It is also recommended to cease the use of this medication for a certain period before and after surgery and to resume only after kidney function has recovered. This medication may decrease vitamin B12 levels, so testing for vitamin B12 deficiency is advisable for long-term users. Elderly patients often experience decreased kidney function, making appropriate dose adjustments and regular kidney function tests important. During the use of this medication, if severe joint pain or blistering skin conditions occur, medical consultation should be sought immediately. This medication is not recommended for children and adolescents, as safety and efficacy have not been established. In case of overdose, gastrointestinal disturbances or lactic acidosis could occur, requiring immediate medical attention.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disturbances
  • cough
  • appetite loss
Show 136 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • lipase increase
  • amylase increase
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • appetite loss
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • dysarthria
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • pneumonia
  • hypertension
  • anxiety
  • depression
  • insomnia
  • pruritus
  • palpitations
  • dry eye
  • cataract
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • drowsiness
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • benign prostatic hyperplasia
  • confusion state
  • nocturia
  • dermatitis
  • hypertension
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased blood creatinine
  • facial swelling
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • headache
  • paresthesia
  • postherpetic neuralgia
  • hemiparesis
  • syncope
  • subdural effusion
  • corneal abrasion
  • fall
  • upper limb fracture
  • voice disorders
  • respiratory distress
  • hearing loss
  • dizziness
  • dyslipidemia
  • hypercholesterolemia
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain storage temperatures between 1 and 30 degrees Celsius to preserve its efficacy over time.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

60 tablets/box [10 tablets/PTPX6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.